Trial Parameters
Brief Summary
This study is a prospective, acute, first-in-human, early feasibility study intended to assess the initial safety and performance of the Agilis™ Radiofrequency (RF) Transseptal (TSP) System in crossing the atrial septum for left atrial and left ventricular access during cardiac electrophysiology (EP) and interventional cardiology (IC) procedures. This study will be conducted in an acute setting. Subjects will be followed through hospital discharge, and no follow-up visits will be required for this study.
Eligibility Criteria
Inclusion Criteria: * Is able and willing to provide written informed consent prior to any clinical investigation-related procedure * Plans to undergo an ablation procedure in LA, LV or concomitant procedure with ablation and LAAO device implantation requiring transseptal puncture * Is at least 18 years of age * Able and willing to comply with all study requirements Exclusion Criteria: * Currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from the study Sponsor * Pregnant or nursing * Known presence of intracardiac thrombus * Known existing circumferential pericardial effusion (\>2 mm) * Previous interatrial septal patch or prosthetic atrial septal defect closure device * Any previous thromboembolic event with in the last 6 months * Known or suspected left atrial myxoma * Known or suspected myocardial infarction within the last two weeks * Unstable an